BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14:41. [PMID: 28231805 DOI: 10.1186/s12985-017-0710-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Zhou Q, Rong L, Rong D, Yang Y, Hao J, Zhang Z, Ma L, Rao G, Zhou Y, Xiao F, Li C, Wang H, Li YP. Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells. Antiviral Res 2021;193:105136. [PMID: 34252495 DOI: 10.1016/j.antiviral.2021.105136] [Reference Citation Analysis]
2 Liu J, Guo M, Ke L, You R. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. Front Public Health 2022;10:836986. [DOI: 10.3389/fpubh.2022.836986] [Reference Citation Analysis]
3 Kong F, Wen X, Wen X, Wang X, Wu G, Lin S, Wang L, Xing H, Yan X, Zheng S, Ning Q, Wang Z, Zhang L, Lin J, Tong Z, Huang C, Su M, Tong L, Jia J, Xin Y, Zhu Q, Wang J, Chen L, Li X, Wu X, Niu D, Liu Q, Wei W, Zhang Y, Li G, Niu J. Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. J Gastroenterol Hepatol 2021. [PMID: 33491236 DOI: 10.1111/jgh.15412] [Reference Citation Analysis]
4 Jiang X, Lv X, Chang L, Yan Y, Ji H, Sun H, Guo F, Rodgers MA, Yin P, Wang L. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors. Antiviral Res 2020;181:104871. [PMID: 32717286 DOI: 10.1016/j.antiviral.2020.104871] [Reference Citation Analysis]
5 Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of hepatitis C virus genotypes in Istanbul, Turkey. Indian J Med Microbiol 2018;36:192-6. [PMID: 30084409 DOI: 10.4103/ijmm.IJMM_17_381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Torresi J. The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine. Front Microbiol 2017;8:2163. [PMID: 29163442 DOI: 10.3389/fmicb.2017.02163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Qu LX, Shi Y, Chen KY, Lu YH, Ren H. The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study. BMC Infect Dis 2021;21:974. [PMID: 34536999 DOI: 10.1186/s12879-021-06577-8] [Reference Citation Analysis]
8 Lei JH, Liang J, Gong X, Xiao XQ, Chen Z, Peng F. Analysis of Transmission Routes of Hepatitis C Virus Based on Virus Genotyping in 341 Cases with Different Suspected Initial Infection Time Points in Hunan Province, China. Med Sci Monit 2018;24:5232-41. [PMID: 30055000 DOI: 10.12659/MSM.907424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Huang R, Rao H, Xie Q, Gao Z, Li W, Jiang D, Mo H, Massetto B, Stamm LM, Brainard DM, Wei L. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol 2019;91:1313-8. [PMID: 30861150 DOI: 10.1002/jmv.25454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Lei JH, Gong X, Xiao XQ, Chen Z, Peng F. Genotype distribution of hepatitis C virus in 952 cases from 2014 to 2016 in Hunan Province, China. Arch Med Sci 2018;14:1055-60. [PMID: 30154888 DOI: 10.5114/aoms.2017.70664] [Reference Citation Analysis]
11 Ranjbar Kermani F, Amini Kafi-Abad S, Mousavi Hossein K, Maghsudlu M, Sharifi Z, Mansournia MA. Association of HCV genotype with viral load among Iranian blood donors: a penalized logistic regression. Med J Islam Repub Iran 2019;33:149. [PMID: 32280655 DOI: 10.34171/mjiri.33.149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Yang J, Liu HX, Su YY, Liang ZS, Rao HY. Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020. World J Clin Cases 2022; 10(14): 4480-4493 [DOI: 10.12998/wjcc.v10.i14.4480] [Reference Citation Analysis]
13 Wei K, Jiang BC, Guan JH, Zhang DN, Zhang MX, Wu JL, Zhu GZ. Decreased CD4+CD25+CD127dim/- Regulatory T Cells and T Helper 17 Cell Responsiveness to Toll-Like Receptor 2 in Chronic Hepatitis C Patients with Daclatasvir Plus Asunaprevir Therapy. Viral Immunol 2018;31:559-67. [PMID: 30067145 DOI: 10.1089/vim.2018.0055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet 2019;44:43-52. [PMID: 29909549 DOI: 10.1007/s13318-018-0492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Tang Q, Wei L, Liu X, Hu P. Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. Infect Drug Resist 2021;14:2297-307. [PMID: 34188496 DOI: 10.2147/IDR.S312902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhao Z, Chu M, Guo Y, Yang S, Abudurusuli G, Frutos R, Chen T. Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives. Front Microbiol 2022;13:884598. [PMID: 35722351 DOI: 10.3389/fmicb.2022.884598] [Reference Citation Analysis]
17 Zhang Y, Gao Z, Wang S, Liu J, Paul N, He T, Liu C, Zhang H, Lv Y, Cao R, Mao W, Wan J, Ma H, Huang M, Liu Y, Wang J, Liao P, Zeng P, He M, Shan H. Hepatitis C virus genotype/subtype distribution and evolution among Chinese blood donors: Revealing recent viral expansion. PLoS One 2020;15:e0235612. [PMID: 32649673 DOI: 10.1371/journal.pone.0235612] [Reference Citation Analysis]
18 Li M, Zhuang H, Wei L. How would China achieve WHO's target of eliminating HCV by 2030? Expert Rev Anti Infect Ther 2019;17:763-73. [PMID: 31578079 DOI: 10.1080/14787210.2019.1675509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
19 Wang Y, Chen X, Ye M, Pang W, Zhang C, Xiong SD, Zheng YT. Consistency of spatial dynamics of HIV-1 and HCV among HIV-1/HCV coinfected drug users in China. BMC Infect Dis 2021;21:1001. [PMID: 34563139 DOI: 10.1186/s12879-021-06711-6] [Reference Citation Analysis]
20 Chatterjee K, Gupta R, Omar BJ, Gupta P, Kalita D. Genotypic distribution of hepatitis C virus in Uttarakhand. Indian J Med Microbiol 2021:S0255-0857(21)04133-5. [PMID: 34210508 DOI: 10.1016/j.ijmmb.2021.06.009] [Reference Citation Analysis]
21 Hu C, Yuan G, Liu J, Huang H, Ren Y, Li Y, Chen X, Li W, Wu T, Deng H, Peng Y, Zhang YY, Zhou Y. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. Can J Gastroenterol Hepatol 2018;2018:3908767. [PMID: 30538973 DOI: 10.1155/2018/3908767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
22 Chen JH, Zeng Z, Zhang XX, Zhang Y, Zhang RW, Wang S, Wu CH, Yu M, Liu D, Xi HL, Zhou YX, An YY, Xu XY. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting. World J Gastroenterol 2017; 23(22): 4072-4079 [PMID: 28652660 DOI: 10.3748/wjg.v23.i22.4072] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
23 Gao T, Chai W, Shi L, Shi H, Sheng A, Yang J, Li G. A new colorimetric assay method for the detection of anti-hepatitis C virus antibody with high sensitivity. Analyst 2019;144:6365-70. [DOI: 10.1039/c9an01466g] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhou HJ, Cao J, Shi H, Naidoo N, Semba S, Wang P, Fan YF, Zhu SC. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Front Public Health 2021;9:779215. [DOI: 10.3389/fpubh.2021.779215] [Reference Citation Analysis]
25 Peng H, Zhang L, Feng Y, Tang H, Luo Z, Qi Z, Xia X, Zhao P. A cross-sectional serum investigation of a clustering hepatitis C virus infection in Southwest China. J Med Virol 2019;91:508-13. [PMID: 30204254 DOI: 10.1002/jmv.25315] [Reference Citation Analysis]
26 Tran L, Nhu Y M, Le Ba Nghia T, Hendam A, Vuong NL, Alzalal E, Sayed AM, Hussain MM, Sharma A, Tieu T, Mathenge PG, Hirayama K, Alexander N, Huy NT. Frequent inappropriate use of unweighted summary statistics in systematic reviews of pathogen genotypes or genogroups. J Clin Epidemiol 2020;119:26-35. [PMID: 31740320 DOI: 10.1016/j.jclinepi.2019.11.009] [Reference Citation Analysis]
27 Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372 [PMID: 29599611 DOI: 10.3748/wjg.v24.i12.1361] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
29 Chen B, Ma ZH, Xu B, Chang H, He XX, Pei LJ, Ren YN, Xing WG. Evaluation of seven rapid diagnostic tests for detection of hepatitis C virus antibodies in China. J Viral Hepat 2021;28:657-63. [PMID: 33421262 DOI: 10.1111/jvh.13466] [Reference Citation Analysis]
30 Ling YM, Chen JY, Guo L, Wang CY, Tan WT, Wen Q, Zhang SD, Deng GH, Lin Y, Kwok HF. β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development. Sci Rep 2017;7:13404. [PMID: 29042578 DOI: 10.1038/s41598-017-13332-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
31 Kamal SM, Ghoraba D. Epidemiology and Modes of Transmission of HCV in Developing Countries. Hepatitis C in Developing Countries. Elsevier; 2018. pp. 13-22. [DOI: 10.1016/b978-0-12-803233-6.00002-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 Young J, Wong S, Janjua NZ, Klein MB. Comparing direct acting antivirals for hepatitis C using observational data - Why and how? Pharmacol Res Perspect 2020;8:e00650. [PMID: 32894643 DOI: 10.1002/prp2.650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Reference Citation Analysis]
35 Liu Y, Ye S, Xiao X, Zhou T, Yang S, Wang G, Sun C, Zhang B, Wang G. Association of diabetes mellitus with hepatitis B and hepatitis C virus infection: evidence from an epidemiological study. Infect Drug Resist 2019;12:2875-83. [PMID: 31686868 DOI: 10.2147/IDR.S218536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Chen M, Zheng F, Yuan G, Duan X, Rong L, Liu J, Feng S, Wang Z, Wang M, Feng Y, Zhou Q, Li J, Deng K, Li C, Xia J, Rao G, Zhou Y, Fu Y, Li YP. Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals. Front Microbiol 2018;9:2950. [PMID: 30564209 DOI: 10.3389/fmicb.2018.02950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Han Q, Fan X, Wang X, Wang Y, Deng H, Zhang X, Zhang K, Li N, Liu Z. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virol J 2019;16:74. [PMID: 31159813 DOI: 10.1186/s12985-019-1184-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Namayandeh M, Jamalidoust M, Heydari Marandi N, Aliabadi N, Ziyaeyan A, Pouladfar G, Ziyaeyan M. Hepatitis C virus genotypes in patients with chronic hepatitis C infection in southern Iran from 2016 to 2019. Microbiol Immunol 2020;64:762-7. [PMID: 32902892 DOI: 10.1111/1348-0421.12845] [Reference Citation Analysis]
39 Wang X, Wei L. Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. J Clin Transl Hepatol 2021;9:419-27. [PMID: 34221928 DOI: 10.14218/JCTH.2020.00097] [Reference Citation Analysis]
40 Mei X, Lu H. Prevalence, diagnosis, and treatment of hepatitis C in Mainland China. Glob Health Med 2021;3:270-5. [PMID: 34782868 DOI: 10.35772/ghm.2021.01080] [Reference Citation Analysis]
41 Zhang J, Sun W, Lin J, Tian Y, Ma L, Zhang L, Zhu Y, Qiu W. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China. BMC Infect Dis 2019;19:645. [PMID: 31324230 DOI: 10.1186/s12879-019-4217-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Li W, Liang J, An J, Liu L, Hou Y, Li L, Zhao W, Cui L, Xue N, Al-dhamin Z, Han T, Nan Y, Zhang L, Granito A. Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-11. [DOI: 10.1155/2022/7395506] [Reference Citation Analysis]
43 Miao M, Jing X, De Clercq E, Li G. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020;14:2759-74. [PMID: 32764876 DOI: 10.2147/DDDT.S254754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
44 Yang X, Ding T, Huang H, Xu Y, Yu J, Chen Z. Development and validation of a simple and rapid method for hepatitis C virus genotyping based on one-step RT-qPCR. Exp Ther Med 2020;20:2284-90. [PMID: 32765706 DOI: 10.3892/etm.2020.8912] [Reference Citation Analysis]
45 Du G, Li X, Musa TH, Ji Y, Wu B, He Y, Ni Q, Su L, Li W, Ge Y. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. J Med Virol 2019;91:401-10. [PMID: 30192393 DOI: 10.1002/jmv.25311] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Li H, Yang Z, Zhang S, Xu L, Wei Y, Jiang J, Caro L, Feng HP, McCrea JB, Li M, Xie S, Wang J, Zhao XM, Mu S. A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants. Clin Pharmacol 2020;12:1-11. [PMID: 32104104 DOI: 10.2147/CPAA.S224662] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Cheung TT, Yan Chiu JW, Yuen MF, Ling Lam KS, Yung Cheung BM, Feng HP, Yeh WW, Wang J, Li W, Zhao XM, Wang Z, Mu S. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. Clin Ther 2018;40:719-732.e1. [PMID: 29724498 DOI: 10.1016/j.clinthera.2018.03.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]